Recent advances in molecular cell biology have led to the exploration of new therapies
based on molecules, cells, and genes to treat a variety of ocular disorders. In this review, we …

The eye is at the forefront of developing therapies for genetic diseases. With the FDA
approval of the first gene-therapy drug for a form of congenital blindness, numerous studies …

Recent advances in surgical techniques, therapeutic approaches and materials sciences
have produced revolutionary new therapies for ocular diseases. The development of …

Ocular gene therapy involves the introduction of an exogenous gene product to a host's
cellular and genetic machinery for endogenous production of a desired gene product. The …

The question of where gene therapy is going has almost as many answers as there are
practitioners in the field. Narrowing our focus to diseases of the eye, this diversity of opinions …

Over the last few years, huge progress has been made with regard to the understanding of
molecular mechanisms underlying the pathogenesis of neurodegenerative diseases of the …

Since long before the first approval of gene therapy for retinal disease, ocular gene therapy
has captured the hopes of patients, clinicians, and scientists alike. Indeed, the retina …

Non-viral vectors for potential gene replacement and therapy have been developed in order
to overcome the drawbacks of viral vectors. The diversity of non-viral vectors allows for a …

The clinical treatment of diseases affecting the eye globe, and specifically the retina and
posterior eye segment, is often hindered by the physiological protection structures and …

Gene therapy is a novel form of drug delivery that enlists the synthetic machinery of the
patient's cells to produce a therapeutic agent. Genes may be delivered into cells in vitro or in …